top of page

Lead Product

ellennbe's lead product in the field of immune-mediated inflammatory diseases (IMIDs)

is a new and innovative therapeutic approach.


We currently cover the following indications: 


  • Rheumatoid Arthritis (RA)

  • Juvenile Idiopathic Arthritis (JIA)

  • Ankylosing Spondylitis

  • Polymyalgia Rheumatica

  • Polyarthritis


  • Morbus Crohn

  • Ulcerative Colitis


  • Orphan disease:

      Anti-Synthetase Syndrome


*Treatment planned

First clinical results in patients have been impressive, with reductions in both inflammation and swelling, and proven efficacy in long-term treatment. Patients report a distinctly higher quality of life soon after initial treatment (i. e. HAQ).


The following treatment benefits are identified: 

  • Quick efficacy with first effects within 24 hours (reduction of pain and stiffness)

  • ellennbe’s lead product is compatible with standard therapies (e. g. csDMARDs, bDMARDs, glucocorticoids) other than JAK inhibitors. 

  • During the treatment, standard therapies (e. g. csDMARDs, bDMARDs, glucocorticoids) were de-escalated, no reactivation was detected, and improvements were achieved.

  • Positive therapeutic response in patients after failure of bDMARDs

  • Curative character under long-term treatment detected

  • Self-application possible

  • Reasonable superior safety profile

Three single case studies are illustrated below: 

Rheumatoid Arthritis: Single Case 1

Under ellennbe's treatment, excellent disease control for over 2.5 years is achieved. After the second treatment, the patient slept through the night and could walk forward down the stairs for the first time in years. Presently, the patient is so far under remission of the disease with control of status every two months. 

Furthermore, within the first two weeks of ellennbe’s treatment a decrease in the amount of tender and swollen joints, and in patient’s rating of pain, impairment due to RA and disease activity was observed and have been maintained until today.

After the second treatment:

  • The patient slept the night through.

  • The patient was able to walk down the stairs forward for the first time in years.

CRP is increased since the patient is insanely stressed:

  • Start of attendance classes after the coronavirus pandemic (teacher)

  • Start to care for the mother, which would have been impossible before the start of treatment.

Patient had no joint complaints at all.​

CRP reestablished to below 1 two weeks after the mother's death and stress relief
Still no joint complaints.

Rheumatoid Arthritis: Single Case 2

Previous treatments with DMARDs (i. e. TNF-α inhibitors, JAK inhibitors, MTX) and Quensyl® failed. The patient was under treatment with tocilizumab, still suffering severely from disease symptoms such as swollen and inflamed joints. 

Additional treatment with ellennbe's novel treatment method resulted in a significant reduction in HAQ-score after 6 weeks. Similar to the patient above, within the first two weeks of ellennbe’s treatment a decrease in the amount of tender and swollen joints, and in patient’s rating of pain, impairment due to RA and disease activity was observed and have been maintained until today. 

After 16 weeks, the treatment with tocilizumab was discontinued without any effect on the improved health condition.  


The patient underwent finger surgery shortly before treatment start to reduce synovitis among others. Under treatment with ellennbe‘s technology, there has been no reactivation of synovitis on the finger joints.

Assessment of CRP was not informative in this patient due to the use of tocilizumab, an IL-6 inhibitor. However, after tocilizumab discontinuation, no increase in CRP was observed.

The patient is still under ellennbe's treatment for almost 2 years without taking any DMARDs again. 

Anti-Synthetase Syndrome (ASyS): Single Case 3

Anti-synthetase syndrome (ASyS) is a rare autoimmune condition with clinical features that can include triad of myositis, arthritis, and interstitial lung disease. Patients with anti-synthetase syndrome often require multi-modality immunosuppressive therapy to control the muscle and/or pulmonary manifestations of their disease. The long-term care of these patients mandates careful attention to the adverse effects and complications of chronic immunosuppressive therapy. Symptoms of the disease are often severe and rapidly progressive. 

Patient (58 years, female)

  • has been suffering from ASyS for 3 years.

  • Triad of the symptoms were severly present.

  • Condition did not improve over the years.

  • Extensive previous treatments, including rescue medication Cyclophosphamide, without therapeutic benefit.

"Overall, the change is amazing! My muscle and joint pain is completely gone. My breathing is definitely better, except for an outlier last Friday. (…) Another positive aspect is that I was able to walk an average of 5 kilometres a day last week (not completely pain-free, but okay). That wasn't possible before! My knees have also calmed down again in the night.

I no longer have night pain. Overall, my strength and stamina are increasing and so is my good mood. (…) It is absolutely important to me to support you (ellennbe) if the treatment is successful, so that as many patients as possible are lucky enough to be able to try this treatment."

bottom of page